Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.63 |
| ▸ | AGT | P01019 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429199 | 0.94 | AGTR1 (0.56) | AGTR2AGTR1AGT | |
| SCHEMBL809 | 0.92 | AGT (0.57) | AGTR2AGTR1AGT | |
| SCHEMBL7310565 | 0.92 | AGTR1 (0.59) | AGTR2AGTR1AGT | |
| SCHEMBL7312342 | 0.91 | AGTR1 (0.58) | AGTR2AGTR1AGT | |
| SCHEMBL9313215 | 0.91 | AGTR2 (0.56) | AGTR2AGTR1AGT | |
| SCHEMBL7310270 | 0.90 | AGTR1 (0.57) | AGTR2AGTR1AGT | |
| SCHEMBL7308711 | 0.90 | AGTR1 (0.59) | AGTR2AGTR1AGT | |
| SCHEMBL7303307 | 0.89 | AGTR1 (0.56) | AGTR2AGTR1AGT | |
| SCHEMBL9947753 | 0.89 | AGT (0.58) | AGTR2AGTR1AGT | |
| SCHEMBL12991424 | 0.89 | AGT (0.58) | AGTR2AGTR1AGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250168-B1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-RE44873-E1 | Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof | SALUBRIS ASSET MANAGEMENT CO., LTD. (CN) | 2014-04-29 | — | — | US | disclosed |
| US-RE44873-E1 | Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof | SALUBRIS ASSET MANAGEMENT CO., LTD. (CN) | 2014-04-29 | — | — | US | disclosed |
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2244575-B1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-1988090-B1 | IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES, PREPARATION METHODS AND USE THERROF | SALUBRIS ASSET MAN CO LTD (CN) | 2013-05-01 | — | — | EP | disclosed |
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8293777-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME, CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8252825-B2 | Angiotensin II receptor antagonists | NICOX (IT) | 2012-08-28 | — | — | US | disclosed |
| WO-2009106470-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009099853-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009094242-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009070241-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070241-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-02-05 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076247-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076246-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | AGTR2, AGTR1, REN | AGTR2 1/4885AGTR1 2/4885AGT 9/4885 |
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885AGT 10/4885 |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885AGT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.